A systematic review of every published human study of BPC-157 found three, covering 30 people in total, none of them with a control group. All three reported that most participants felt better and none reported a treatment-related side effect, but the authors rated the overall certainty of that evidence as very low. For anyone weighing the peptide for a sore knee or a slow-healing tendon, the finding is less that BPC-157 fails than that, in people, it has barely been tested.
What the review found
The review, whose corresponding author lists a University of Nottingham address, was registered in advance on PROSPERO and searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to 1 June 2026. It accepted any study of BPC-157 in human participants, for any purpose. Only three qualified.
The largest was a retrospective review of 16 people who received BPC-157 injections into the knee for pain. The second was a retrospective pilot of 12 people with interstitial cystitis, a chronic bladder condition, who received it into the bladder. The third was a prospective safety pilot in which two people received it intravenously. That makes 30 participants across three different routes and three different conditions, so the studies cannot be pooled into a single estimate of anything.
The authors judged all three to be of poor methodological quality using a National Institutes of Health tool for before-and-after studies with no control group, and graded certainty using the GRADE framework, downgrading for serious risk of bias, indirectness and imprecision. With no comparison group, an improvement in pain cannot be separated from the natural course of the condition, from the placebo effect of an injection, or from whatever else the patients were doing at the time.
How it fits
Most of what is claimed for BPC-157 rests on animal studies, which the review acknowledges, and our BPC-157 research page sets out that body of work. This review adds the human side of the ledger, and it is very thin. The absence of reported adverse events is not reassurance either: two of the three studies looked back at records, and 30 people is far too few to detect anything but a common harm. The authors conclude that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality clinical trials.
What is not yet known
Almost everything a buyer would want to know. There is no controlled human trial of BPC-157 for any musculoskeletal injury in this review, no data on how product sold online compares with what was studied, and no long-term safety information. This article is based on the published abstract; the full text was not available to us, so details of each included study beyond what the abstract reports have not been checked.
Sources: Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica, 8 October 2026 (doi: 10.52628/92.3.15837; PROSPERO CRD420261406325).
